Enhancing Cardioprotection Through Neutrophil‐Mediated Delivery of 18β‐Glycyrrhetinic Acid in Myocardial Ischemia/Reperfusion Injury
Advanced Science · 2024-11 · 11 (42)
DOI: 10.1002/advs.202406124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 12.09.2024. Verfasst von Dongjian Han und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, Glycyrrhetinic Acid, Neutrophils, Disease Models, Animal. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Henan key research and development projects.
Abstract (Originalsprache)
Myocardial ischemia/reperfusion injury (MI/RI) generates reactive oxygen species (ROS) and initiates inflammatory responses. Traditional therapies targeting specific cytokines or ROS often prove inadequate. An innovative drug delivery system (DDS) is developed using neutrophil decoys (NDs) that encapsulate 18β‐glycyrrhetinic acid (GA) within a hydrolyzable oxalate polymer (HOP) and neutrophil membrane vesicles (NMVs). These NDs are responsive to hydrogen peroxide (H 2 O 2 ), enabling controlled GA release. Additionally, NDs adsorb inflammatory factors, thereby reducing inflammation. They exhibit enhanced adhesion to inflamed endothelial cells (ECs) and improved penetration. Once internalized by cardiomyocytes through clathrin‐mediated endocytosis, NDs protect against ROS‐induced damage and inhibit HMGB1 translocation. In vivo studies show that NDs preferentially accumulate in injured myocardium, reducing infarct size, mitigating adverse remodeling, and enhancing cardiac function, all while maintaining favorable biosafety profiles. This neutrophil‐based system offers a promising targeted therapy for MI/RI by addressing both inflammation and ROS, holding potential for future clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
- Key Laboratory of Cardiac Injury and Repair of Henan Province, Zhengzhou, 450018, China.
- Department of Vascular and Endovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
ORCID-Profile: Dongjian Han, Deliang Shen
Förderung
- National Natural Science Foundation of China
- Henan key research and development projects
Zitieren
APA
Han, D., Wang, F., Jiang, Q., Qiao, Z., Zhuang, Y., An, Q., Li, Y., Tang, Y., Li, C., & Shen, D. (2024). Enhancing Cardioprotection Through Neutrophil‐Mediated Delivery of 18β‐Glycyrrhetinic Acid in Myocardial Ischemia/Reperfusion Injury. Advanced Science, 11(42). https://doi.org/10.1002/advs.202406124
Vancouver
Han D, Wang F, Jiang Q, Qiao Z, Zhuang Y, An Q, et al. Enhancing Cardioprotection Through Neutrophil‐Mediated Delivery of 18β‐Glycyrrhetinic Acid in Myocardial Ischemia/Reperfusion Injury. Advanced Science. 2024;11(42). doi:10.1002/advs.202406124
BibTeX
@article{Han2024,
author = {Han, Dongjian and Wang, Fuhang and Jiang, Qingjiao and Qiao, Zhentao and Zhuang, Yuansong and An, Quanxu and Li, Yuhang and Tang, Yazhe and Li, Chenyao and Shen, Deliang},
title = {Enhancing Cardioprotection Through Neutrophil‐Mediated Delivery of 18β‐Glycyrrhetinic Acid in Myocardial Ischemia/Reperfusion Injury},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {42},
doi = {10.1002/advs.202406124}
}
EUVIMED